1. Introduction {#sec1-ijms-21-03040}
===============

Hypertrophic cardiomyopathy (HCM) is a global, inherited cardiovascular disease that can lead to arrhythmia, heart failure and even sudden cardiac death \[[@B1-ijms-21-03040],[@B2-ijms-21-03040]\]. It is characterized by ventricular hypertrophy (usually the left ventricle), small ventricular cavity, and decreased ventricular diastolic compliance. The prevalence of HCM is estimated at 0.2% of the general population by early echocardiographic studies \[[@B2-ijms-21-03040]\]. The utilization of cardiac magnetic resonance imaging (MRI) and genetic testing has increased recognition and precise clinical diagnosis of HCM \[[@B3-ijms-21-03040],[@B4-ijms-21-03040]\]. Genetic testing, though, has revealed that some mutation carriers do not exhibit obvious clinical symptoms of HCM. It is still possible for a carrier to later demonstrate HCM symptoms and to pass these potentially pathogenic mutations on to offspring \[[@B5-ijms-21-03040]\]. With the use of these more sophisticated technologies, the prevalence of HCM should be modified to 0.5% or even greater \[[@B2-ijms-21-03040]\].

Variants in sarcomere and sarcomere-associated protein genes represent the greatest genetic contributor to HCM cases. Previous studies have shown that pathogenic mutations in myosin heavy chain 7 (*MYH7*) and cardiac myosin-binding protein C (*MYBPC3*) account for 60%--70% of identified HCM cases \[[@B6-ijms-21-03040]\]. About 1%--5% of HCM and HCM-like phenotypes can be attributed to pathogenic mutations in other sarcomere protein genes (e.g., *TNNT2*, *TNNI3*, *TPM1*, *MYL2*, *MYL3*, *ACTC1*, and *TNNC1*) and some non-sarcomere protein genes (e.g., Z-disk and calcium-handling proteins) \[[@B6-ijms-21-03040],[@B7-ijms-21-03040]\].

HCM represents a genetically complex and heterogeneous disease \[[@B7-ijms-21-03040]\]. High throughput sequencing technologies have greatly reduced the cost of genetic testing in familial HCM screening, and numerous disease-causing variants had been identified and archived \[[@B8-ijms-21-03040],[@B9-ijms-21-03040],[@B10-ijms-21-03040]\]. Related individuals carrying an identical mutation in the same gene, may display different HCM phenotypes and experience different clinical outcomes \[[@B11-ijms-21-03040]\], suggesting that novel causative or modifier genes exist or that non-coding RNAs, such as microRNA (miRNA) and long noncoding RNA (lncRNA). Furthermore, the complex HCM phenotype may result, not from monogenic or even digenic perturbation, but from the synergy of a complex gene co-expression network. With our current understanding of cardiomyopathy genetics, genotype--phenotype correlation may not be obvious in HCM patients. Since the genetic modifier and pathway/co-expression perspectives are both possibilities, distinguishing pathogenic genes and variants and establishing clear genotype--phenotype correlations remain challenging.

Previously, Gu *et al*. \[[@B12-ijms-21-03040]\] generated 37 myocardial RNA-seq data from HCM patients and healthy donors. Their research mainly focused on RNA-seq data quality evaluation, novel lncRNA gene prediction, and differential expression analysis. The results demonstrated that a high-quality dataset was obtained and hundreds of differentially expressed genes (DEGs) were identified between HCM patients and healthy controls. In this study, we systemically analyzed this dataset with a different perspective. This included the identification of functional variants, differentially expressed coding and noncoding genes, and interpretation of their potential functional roles associated with HCM. In addition, we also performed weighted gene co-expression network analysis (WGCNA) and protein--protein interaction (PPI) network analysis to identify a gene network that was associated with HCM clinical traits.

2. Results {#sec2-ijms-21-03040}
==========

2.1. Statistics of RNA-Seq Data {#sec2dot1-ijms-21-03040}
-------------------------------

The myocardial RNA-seq included 28 HCM patients and 9 healthy controls. For HCM samples, *MYBPC3* mutations were previously identified in 10 samples and *MYH7* mutations in eight ([Table 1](#ijms-21-03040-t001){ref-type="table"}). The other 10 remained genetically undiagnosed ([Table 1](#ijms-21-03040-t001){ref-type="table"}). The RNA-seq data generated 4.3 billion reads with an average of 116.5 million per sample. After quality control, read mapping, variant calling, and filtering, \~0.75 million variants, including single nucleotide polymorphisms (SNPs) and insertions and deletions (Indels), on average, were identified for each sample. Approximately 34,000 variants were located in exonic regions. The summary statistics of the RNA-seq data are listed in [Table 2](#ijms-21-03040-t002){ref-type="table"}.

2.2. Pathogenic Variants and Genes Prioritization {#sec2dot2-ijms-21-03040}
-------------------------------------------------

In order to identify the pathogenic variants and genes responsible for the development of HCM, we applied a series of bioinformatics filters to the exonic variants identified in the HCM patients ([Figure 1](#ijms-21-03040-f001){ref-type="fig"}). We identified over 4000 candidate variants that matched our criteria: 1) variants only existed in the HCM patients, 2) variants classified as nonsynonymous, stop-gain, stop-loss, frameshift, or splice altering, 3) variants with minor allele frequency less than 0.01 in human populations, and 4) variants predicted to be deleterious in silicon. In order to further narrow down the candidate lists, we filtered the above variants with the 73-gene HCM panel ([Supplementary Data 1](#app1-ijms-21-03040){ref-type="app"}). This resulted in a total of 43 potential candidate variants, and 19 genes were prioritized ([Figure 2](#ijms-21-03040-f002){ref-type="fig"} and [Table 3](#ijms-21-03040-t003){ref-type="table"}). Therefore, our following analysis and discussions were mainly focused on those 19 genes, and the 4000 candidate variants were also listed in [Supplementary Data 2](#app1-ijms-21-03040){ref-type="app"} for review.

For the 10 patients with previously identified *MYBPC3* functional mutations, we found nine *MYBPC3* variants (five frameshift variants, three stop-gain variants, and one splicing variant) in nine patients ([Figure 2](#ijms-21-03040-f002){ref-type="fig"} and [Table 3](#ijms-21-03040-t003){ref-type="table"}). HCM518 had a *MYBPC3* mutation in isolation, and *MYBPC3*, *NEXN*, *LDB3*, and *TNNT2* variants were identified in HCM515. For the remaining *MYBPC3* HCM samples, variants were also found in the following other cardiomyopathy genes: *ACTN2*, *LAMA4*, *LDB3*, *NEXN*, *PSEN2*, *TNNT2*, and *TTN*. The remaining patient, HCM486, did not have an identifiable *MYBPC3* variant, but an unreported mutation (c.T106C:p.C36R) was found in *PLN*.

Seven missense *MYH7* variants were found in nine samples ([Figure 2](#ijms-21-03040-f002){ref-type="fig"} and [Table 3](#ijms-21-03040-t003){ref-type="table"}), with two (HCM456 and HCM483) having a *MYH7* mutation in isolation and one (HCM437) possessing *MYH7*, *MYBPC3*, and *COX15* variants. For the remaining *MYH7* HCM samples, variants in the following other cardiomyopathy genes were also found: *DSP*, *MHY6*, *NEBL*, *PSEN1*, *RBM20*, and *TTN*.

We identified eight candidate variants in six genetically undiagnosed patients ([Figure 2](#ijms-21-03040-f002){ref-type="fig"} and [Table 3](#ijms-21-03040-t003){ref-type="table"}). These variants include *ABCC9* (c.T2935C:p.W979R) in HCM541, *SGCD* (c.A845G:p.Q282R) and *TTN* (c.C28730T:p.P9577L) in HCM493, *CSRP3* (c.A585C:p.X195C) in HCM395, *NEXN* (c.C643T:p.R215C) in HCM282, *DSP* (c.G6119A:p.R2040Q) and *PSEN2* (c.G640T:p.V214L) in HCM591, and *NEBL* (c.G561C:p.Q187H) in HCM552. However, we were unable to identify any variants in the remaining four genetically undiagnosed patients ([Figure 2](#ijms-21-03040-f002){ref-type="fig"}).

2.3. Identification of DEGs between HCM Patients and Healthy Controls {#sec2dot3-ijms-21-03040}
---------------------------------------------------------------------

In order to assess the DEGs, we compared gene expression differences between HCM and normal controls by using DEseq2 software. Based on the cut-off threshold (false discovery rate (FDR) \< 0.05 and fold change \> 1.5), a total of 4161 genes were identified as DEGs ([Figure 3](#ijms-21-03040-f003){ref-type="fig"}A and [Supplementary Data 3](#app1-ijms-21-03040){ref-type="app"}), of which 2538 are protein-coding genes, 6 are miRNAs, and 1617 are lncRNAs.

We did not find any significant expression differences for *MYBPC3* and *MYH7* between the groups. However, several genes that have been implicated in cardiomyopathy did demonstrate large differences between normal controls and HCM patients, including *ANKRD1*, *FHL2*, and *TGFB3* ([Figure 3](#ijms-21-03040-f003){ref-type="fig"}B--D). In order to interpret the differentially expressed protein-coding genes, we performed gene over-representation analysis for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The results demonstrated that these genes are largely involved in regulating cardiovascular system development and cardiac physiology. ([Figure 3](#ijms-21-03040-f003){ref-type="fig"}E, [Supplementary Data 4](#app1-ijms-21-03040){ref-type="app"}). Those terms accounted for 7.6% (192 genes) of the DEGs. Pearson correlation analysis revealed that they are significantly co-expressed, even with a multiple correction threshold FDR \< 0.01 ([Figure 4](#ijms-21-03040-f004){ref-type="fig"} and [Supplementary Data 5](#app1-ijms-21-03040){ref-type="app"}). In addition to GO biological processes, we also identified several overrepresented KEGG pathways ([Supplementary Data 4](#app1-ijms-21-03040){ref-type="app"}), including ribosome, cytokine--cytokine receptor interaction, cyclic AMP signaling pathway, and calcium signaling pathways.

There are only six miRNAs that showed significant differences, with *miR-487a*, *miR-654*, *miR-30d*, *miR-154*, and *miR-3193* being downregulated and *miR-3671* being upregulated in HCM patients ([Figure 5](#ijms-21-03040-f005){ref-type="fig"}A--F). Among them, *miR-30d* and *miR-154* have been shown to play regulatory roles in myocardial fibrosis \[[@B13-ijms-21-03040],[@B14-ijms-21-03040]\]. Next, their targeting genes were predicted using miRWalk2. A total of 720 differentially expressed protein-coding genes ([Supplementary Data 6](#app1-ijms-21-03040){ref-type="app"}) were targeted by the above miRNAs, with these genes demonstrating inverse expression patterns compared to their corresponding miRNAs. Among them, 75 are involved in cardiovascular system regulation ([Figure 5](#ijms-21-03040-f005){ref-type="fig"}G). In addition, we also performed the Pearson correlation analysis. The results demonstrated that the percentages of significantly correlated (*p* \< 0.05) candidate pairs ranged from 25.5% (*miR-154*) to 76.5% (*miR-3671*).

In order to dissect the functional roles of the differentially expressed lncRNAs, we retrieved a total of 1482 protein-coding genes near (\< 0.5 Mb) those lncRNAs ([Supplementary Data 7](#app1-ijms-21-03040){ref-type="app"}), including cardiomyopathy-related genes: *TTN*, *ACTC1*, *TPM1*, *JPH2*, *ANKRD1*, *DTNA*, *TMPO*, *FHL2*, *CTNNA3*, *GATA4*, *LAMA2*, *PRDM16*, *POLG*, etc. Further GO enrichment analysis illustrated that these genes are significantly enriched in cardiovascular-related categories ([Table 4](#ijms-21-03040-t004){ref-type="table"}), including 95 genes involved in cardiovascular system development (GO:0072358), 75 genes related to heart development (GO:0007507), and 31 genes critical to cardiac muscle tissue development (GO:0048738).

2.4. Co-Expression Network Analysis {#sec2dot4-ijms-21-03040}
-----------------------------------

To gain insight into the functional organization of the transcriptomes from myocardial tissue, we conducted gene co-expression network analysis with WGCNA. By applying data transformation and filtration according to the WGCNA pipeline (see the "Materials and Methods" section), 8417 protein-coding genes were used for constructing gene co-expression networks. With the soft-thresholding power β = 12 determined by scale-free topology ([Figure 6](#ijms-21-03040-f006){ref-type="fig"}A,B), we identified a total of 16 modules ([Figure 6](#ijms-21-03040-f006){ref-type="fig"}C). The module size ranged from 50 genes in module M11 to 2207 genes in module M8. In addition, by performing correlation analysis between the module module eigengenes (MEs) and clinical traits ([Table 1](#ijms-21-03040-t001){ref-type="table"}), several modules were identified to be associated with HCM clinical traits ([Figure 6](#ijms-21-03040-f006){ref-type="fig"}C), including module M14 and M16, which contain *MYH7* and *MYBPC3*, respectively.

2.5. PPI-Subnetwork Analysis for MYH7 and MYBPC3 Modules {#sec2dot5-ijms-21-03040}
--------------------------------------------------------

Next, we explored the PPIs for the genes in the MHY7- and MYBPC3-involved modules (M14 and M16). By performing MCL clustering, we highlighted four subnetworks that could play significant roles in HCM, including one mtDNA-subnetwork and three cardiomyopathy-gene-centered networks: MYBPC3-, MYH7-, and DSP-subnetworks ([Figure 7](#ijms-21-03040-f007){ref-type="fig"}). Next, we performed Pearson correlation analysis for each subnetwork gene against to the HCM phenotype. This identified half of them (18 out of 39 genes), showing significant correlations (*p* \< 0.05) with the measured phenotypes (Supplementary Data 8), including *NDUFS2*, *DSP*, *JUP*, *TNNI1*, etc. These genes could be directly associated with the phenotypes, while the rest may modulate the HCM phenotypes by interacting with those 18 genes.

Besides the subnetwork hub genes, other genes were also found to be associated with cardiomyopathy. For instance, *TPM1*, and *ACTC1*, which are critical for the maintenance of sarcomere thickness \[[@B15-ijms-21-03040],[@B16-ijms-21-03040]\], have been associated with familial HCM \[[@B17-ijms-21-03040],[@B18-ijms-21-03040],[@B19-ijms-21-03040]\]. Truncating mutations in *DES* are associated with inherited skeletal and cardiac myopathies \[[@B20-ijms-21-03040]\]. *TCAP* is required for sarcomerogenesis in striated muscles, and mutations in *TCAP* have been identified in patients with HCM and dilated cardiomyopathy (DCM) \[[@B21-ijms-21-03040]\]. Patients with heterozygous mutations in *JUP* have been diagnosed with HCM \[[@B22-ijms-21-03040],[@B23-ijms-21-03040]\], and reduced cardiac *DSG2* levels appear to be specifically associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) \[[@B24-ijms-21-03040]\]. For the mtDNA-subnetwork, mutations of *MT-ND1*, *MT-ND2*, *MT-ND3*, *MT-ND4*, *MT-ND4L*, *MT-ND5*, *MT-ND6*, *MT-CO1*, *MT-CO2*, *MT-CO3*, *MT-ATP6*, *MT-ATP8*, and *MT-CYB* have been identified in cardiomyopathy patients \[[@B25-ijms-21-03040],[@B26-ijms-21-03040],[@B27-ijms-21-03040],[@B28-ijms-21-03040]\]. Levels of *NDUFV1*, a component of complex I in the electron transport chain, are significantly decreased in the myocardium of DCM patients, and *NDUFS2* gene mutations cause complex I deficiency with associated DCM \[[@B29-ijms-21-03040],[@B30-ijms-21-03040]\].

3. Discussion {#sec3-ijms-21-03040}
=============

3.1. Pathogenic Variant Analysis and Mechanisms of Variant Synergism {#sec3dot1-ijms-21-03040}
--------------------------------------------------------------------

In the current study, nine HCM patients were identified with pathogenic *MYH7* variants and nine with pathogenic *MYBPC3* variants. One patient (HCM437) had both *MYH7* and *MYBPC3* variants, along with one in *COX15*, whose function appears to be essential for cytochrome c oxidase (COX) biogenesis in the electron transport chain (ETC). Mutations in this gene are associated with Leigh syndrome and COX deficiency with infantile HCM, and the presence of this variant is interesting in the context of the enriched mitochondrial PPI-subnetwork ([Figure 7](#ijms-21-03040-f007){ref-type="fig"}) \[[@B31-ijms-21-03040]\]. All of the *MYH7* mutations were missense variants, while the *MYBPC3* mutations were frameshift, nonsense, or splice variants. Missense, rather than truncating, variants in *MYH7* and truncating, rather than missense, variants in *MYBPC3* are well-documented to be the mutational classifications associated with HCM, instead of other cardiomyopathy subtypes \[[@B32-ijms-21-03040],[@B33-ijms-21-03040]\].

A single variant in *NEXN*, *MYH7*, *NEBL*, and *DSP* was replicated in three, two, two, and two HCM patients, respectively. Importantly, the *NEXN* and *DSP* variants have been predominantly classified as "likely benign" within the NCBI ClinVar database; the *NEBL* mutation is described as a variant of uncertain significance. For patients HCM282 and HCM552, the *NEXN* and *NEBL* variants, respectively, occur in isolation, which may mean that the phenotype results from the presence of these variants in conjunction with unidentified modifier variants. The *NEBL* variant has been found in isolation in one Japanese patient with DCM and in conjunction with another cardiomyopathy-associated variant in a Japanese HCM patient \[[@B34-ijms-21-03040]\].

Both of the patients with the *DSP* variant (HCM562 and HCM591) have another cardiomyopathy gene identified. Desmoplakin, which is encoded by *DSP*, is a desmosomal plaque protein, and variants in this gene are implicated in ARVC \[[@B35-ijms-21-03040]\]. *PSEN2* mutations, like the one in HCM591, have been reported in association with familial Alzheimer's disease and DCM, but not HCM, and those associated with DCM impair calcium signaling and handling \[[@B36-ijms-21-03040]\]. The presenilin complex proteolytically processes desmoglein-2 (*DSG2*), another component of the desmosome, and protein networks implicate gene--gene interactions between the presenilin components and a number of desmosomal proteins, including desmoplakin \[[@B37-ijms-21-03040]\]. This provides a mechanism for how these variants may operate synergistically to produce HCM, and the *DSP* variant may be a pro-HCM modifier gene. Overall, the *NEXN*, *NEBL*, and *DSP* mutations may represent important modifier variants, as they are disproportionately represented in this sample population.

The remaining patients without an identified pathogenic *MYBPC3* or *MYH7* variant had mutations in *ABCC9*, *SGCD*, *TTN*, *CSRP3*, and *PLN*. Variants in *ABCC9*, which encodes an ATP-sensitive K^+^ channel, have been implicated in familial atrial fibrillation, sporadic DCM, and hypertrichotic osteochondrodysplasia. DCM variants have been described in exon 38 and likely modify a nucleotide-binding domain in the SUR2A portion of the channel, altering overall channel gating \[[@B38-ijms-21-03040]\]. HCM541′s variant in *ABCC9* is found in exon 24, which corresponds to the SunT domain of the protein (not a transmembrane region), and may represent an HCM mutational hotspot.

*SGCD* encodes the δ component of the sarcoglycan complex, and mutations in this gene are associated with autosomal recessive limb-girdle muscular dystrophy type VI and a mild autosomal dominant DCM phenotype \[[@B39-ijms-21-03040],[@B40-ijms-21-03040]\]. The sarcoglycan complex interacts with the dystrophin complex, which is in turn composed of dystrophin and dystroglycan subunits. The disruption of sarcoglycan components has been linked with a reduced expression of α-dystroglycan at the sarcolemma, and overall dystroglycan knockout has been associated with disruptions in titin expression \[[@B41-ijms-21-03040]\]. Encoded by *TTN*, titin maintains the structure of the sarcomeric unit in both skeletal and cardiac muscle during contraction and interacts with actin filaments and myosin \[[@B42-ijms-21-03040]\]. While both of the variants identified in HCM493 are categorized as "likely benign". The *SGCD* mutation may further disrupt titin networks that are already disorganized by the *TTN* variant itself and thus work synergistically to produce HCM.

*CSRP3* encodes an LIM domain-containing scaffolding protein that maintains the structure of the Z-disk and the costamere and is implicated in actin remodeling and cardiomyocyte differentiation. Mutations in this gene are associated with both familial HCM and DCM \[[@B43-ijms-21-03040],[@B44-ijms-21-03040]\]. HCM395′s unique mutation has not been reported previously. This stop-loss variant extends the protein by 33 amino acids. A similar variant that converts the termination codon to an arginine residue (rather than a cysteine residue) and promotes a 33 amino acid extension has been labeled as a variant of uncertain significance. Further studies are needed to determine if these additional residues alter protein function, structure, and/or the rate of degradation.

Produced by *PLN*, phospholamban is a substrate of protein kinase A (PKA), a cAMP dependent kinase, in cardiomyocytes. The phosphorylation of phospholamban by PKA relieves its inhibition of ATP2A2, a sarcoplasmic reticulum Ca^2+^-ATPase, allowing for the sequestration of calcium ions and cardiac muscle relaxation in diastole \[[@B45-ijms-21-03040],[@B46-ijms-21-03040]\]. Heterozygous *PLN* variants, like the unreported one found in HCM486, have been identified in patients with HCM; the *PLN* inheritance pattern for DCM is less clear \[[@B46-ijms-21-03040],[@B47-ijms-21-03040]\]. Interestingly, this gene participates in both cAMP and calcium signalling pathways, reflecting the significant KEGG pathway enrichment mentioned above ([Supplementary Data 4](#app1-ijms-21-03040){ref-type="app"}).

3.2. HCM Phenotypic Variability from Multi-Gene Modification and Differential Gene Expression {#sec3dot2-ijms-21-03040}
---------------------------------------------------------------------------------------------

While HCM has been attributed to monogenic perturbations in sarcomeric genes, like *MYBPC3* and *MYH7*, there is often dramatic phenotypic variability, even within a single family, with some family members having other cardiomyopathy subtypes, including DCM and ARVC, or hybrid phenotypes. This variability is most likely attributable to the presence of multiple modifier variants, and hints at the concept that cardiomyopathy is a polygenic trait.

Beyond the single gene and synergistic modifier gene perspectives, pathway perspectives illustrate the idea that even single gene mutations may in turn modify other genes in a specific pathway or network. The differences in expression levels of *ANKRD1*, *FHL2*, and *TGFB3* between the HCM patients and normal controls demonstrated this idea. Mutations in *FHL2* have been implicated in HCM, so the reduced expression of these genes in HCM hearts mirrors actual inherited modifications or deficiencies in these proteins \[[@B48-ijms-21-03040],[@B49-ijms-21-03040],[@B50-ijms-21-03040]\]. Other studies have demonstrated that the elevation of *ANKRD1* expression in DCM heart samples correlates with the progression of heart failure, and this reflects the increased expression that we saw in the HCM patients \[[@B51-ijms-21-03040]\]. Finally, HCM is characterized by cardiac fibrosis, and *TGFB3* is an important driver of the fibrosing process \[[@B52-ijms-21-03040]\]. This is illustrated in the elevation of *TGFB3* expression in our HCM samples; likewise, missense *TGFB3* mutations have loosely been associated with HCM itself \[[@B53-ijms-21-03040]\].

3.3. HCM Modulation with Noncoding RNAs {#sec3dot3-ijms-21-03040}
---------------------------------------

As post-transcriptional regulators, both miRNAs and lncRNAs can interfere with gene expression \[[@B54-ijms-21-03040],[@B55-ijms-21-03040]\]. We explored the miRNA and lncRNA expression profiles of HCM patients and healthy controls. Six miRNAs (*miR-487a*, *miR-654*, *miR-30d*, *miR-154*, *miR-3193* and *miR-3671*) were observed to be significantly up- or down-regulated in HCM patients. Among them, Serum *miR-30d* has been reported to be associated with acute heart failure \[[@B56-ijms-21-03040]\] and considered as a biomarker for diffuse myocardial fibrosis in HCM patients \[[@B13-ijms-21-03040]\]. In addition, the expression of *miR-30d-5p* was decreased 1.58-fold in patients with ST-elevated myocardial infarction \[[@B57-ijms-21-03040]\]. *MiR-154* has been reported to promote myocardial fibrosis through β-catenin signaling pathways \[[@B14-ijms-21-03040],[@B58-ijms-21-03040]\]. It is worth noting that the 75 targeted genes in the miRNA-gene network ([Figure 5](#ijms-21-03040-f005){ref-type="fig"}G) are all involved in the cardiovascular system, suggesting those miRNAs may modulate cardiac function by regulating their expression levels. For example, the target gene *FGF1*, known as acidic fibroblast growth factor, shares regulation by *miR-487a* and *miR-154*. A pathophysiologic role for fibroblast growth factors in idiopathic cardiomyopathy has been implicated in the past \[[@B59-ijms-21-03040]\]. Additionally, several voltage-gated calcium channels genes (*CACNA2D1*, *CACNA1B*, *CACNA1S*, *CACNG4*, and *CACNG8*) are also targeted by those miRNAs. It has been reported that mutations in *CACNA2D1* cause a variant of short QT syndrome, which is associated with sudden cardiac death in humans \[[@B60-ijms-21-03040]\].

Several studies have demonstrated the importance of lncRNAs in the cardiovascular system \[[@B61-ijms-21-03040],[@B62-ijms-21-03040]\]. We retrieved a total of 1482 protein-coding genes near the differentially expressed lncRNAs. A few lncRNAs are located in the introns of cardiomyopathy-related genes (e.g., *TTN*, *ACTC1*, *TPM1*, *JPH2*, *ANKRD1*, *DTNA*, *TMPO*, and *FHL2*) or physically close to these genes. The lncRNA-annotated protein-coding genes are enriched in the GO terms of heart development and cardiomyocyte differentiation ([Table 4](#ijms-21-03040-t004){ref-type="table"}), while the enriched terms for the differentially expressed protein-coding genes centered more so on cardiac physiology (contractility, heart rate, and conduction; [Figure 3](#ijms-21-03040-f003){ref-type="fig"}E). This illustrates the idea that HCM can represent both an inherited defect in myocardial development (that may or may not be immediately clinically apparent) and a pathologic process of ventricular remodeling that occurs over an extended period of time due to impaired cardiac, or even renal, function.

3.4. HCM Modulation with Gene Networks {#sec3dot4-ijms-21-03040}
--------------------------------------

Differential expression analysis usually focuses on individual gene perturbations, which cannot dissect their potential interactions. Furthermore, genes with relatively modest expression changes may also contribute to the phenotypes of interest. However, this information was usually underestimated or missed from differential expression analysis. Network-based analysis provides an alternative way to leverage this gap by grouping a subset of tightly co-expressed genes together, which can be defined as a module or network. In this study, we performed gene co-expression network analysis with WGCNA and PPI analysis with STRING. Our results highlighted four subnetworks, mtDNA-, MYBPC3-, MYH7-, and DSP-subnetworks, that may be critical to the progression of HCM. Besides the hub genes of *MYBPC3*, *MYH7*, and *DSP*, these subnetworks also include several genes that have been implicated in cardiomyopathy, such as *TPM1*, *ACTC1* \[[@B17-ijms-21-03040],[@B18-ijms-21-03040],[@B19-ijms-21-03040]\], *DES* \[[@B20-ijms-21-03040]\], *TCAP* \[[@B21-ijms-21-03040]\], *JUP* \[[@B22-ijms-21-03040],[@B23-ijms-21-03040]\], and *DSG2* \[[@B24-ijms-21-03040]\].

In addition, our gene network analysis also highlighted the importance of mitochondrial genes (mtDNA-subnetwork) in HCM. However, those genes are largely neglected on HCM genetic screening panels. Mutations in sarcomeric genes are associated with inefficient energy utilization \[[@B63-ijms-21-03040]\]. When these variants are present in conjunction with heterozygous oxidative phosphorylation mutations, compensations in energy production may not be possible and may contribute to the HCM phenotypes. This will require further elucidation, but screening for these genes may aid in the identification of a genetic cause of HCM in patients with mutations not included on typical HCM panels and can supplement the landscape of genetic modifiers in HCM.

3.5. Novelty and Limitations of This Study {#sec3dot5-ijms-21-03040}
------------------------------------------

As the original research of this RNA-seq data \[[@B12-ijms-21-03040]\] was reported as data descriptor, with the major findings of this dataset is to be of high quality to perform downstream analysis such as the identification of DEGs. Compared with the original findings, our research highlighted several novel findings. First, we performed a variant calling from this RNA-seq data, our results not only confirmed the *MYH7* and *MYBPC3* pathogenic variants that have been identified in the original research, but also discovered eight candidate variants in six genetically undiagnosed patients. In addition, we also found most of the patients carry muti-genic variants, even for the *MYH7* and *MYBPC3* diagnosed patients, suggesting that a heterogeneous phenotype could exist among those patients. Second, we identified thousands of differentially expressed coding and noncoding genes. For the coding genes, we performed functional enrichment analysis, which highlighted that those genes significantly involved in regulating cardiovascular system development and cardiac physiology (192 genes, [Figure 4](#ijms-21-03040-f004){ref-type="fig"}). We found six differentially expressed miRNAs ([Figure 5](#ijms-21-03040-f005){ref-type="fig"}A--F) that could regulate HCM progression by targeting 75 cardiovascular-function-related genes ([Figure 5](#ijms-21-03040-f005){ref-type="fig"}G). Additionally, by co-locating the differentially expressed lncRNAs and protein-coding genes, we highlighted that several lncRNAs could relate to cardiac function, since they are co-located with the well-known cardiomyopathy-related genes ([Table 3](#ijms-21-03040-t003){ref-type="table"}). Therefore, our analysis not only identified the DEGs, but also reduced the candidates from thousands of DEGs to a few dozen by integrating no-coding gene annotation and gene function enrichment analysis. Last, we performed gene network analysis based on WGCNA and PPI. This resulted in four subnetworks that are strongly correlated to the HCM clinical traits ([Figure 6](#ijms-21-03040-f006){ref-type="fig"} and [Figure 7](#ijms-21-03040-f007){ref-type="fig"}). Those subnetworks not only include known genes implicated in HCM, but also highlighted several genes with an unknown function in HCM that need to be further deciphered ([Figure 7](#ijms-21-03040-f007){ref-type="fig"}).

There are several limitations for our studies. First, calling variants from RNA-seq is confronted with several issues, due to the complexity of the transcriptome. In order to avoid false positives/negatives, we applied SNP and Indel calling with the recommendation of the Broad Institute's GATK best practices workflow. In addition, for the candidate variants, we also "eye" inspected the alignment to avoid false positive/negatives raised by too much complexity around the variant region. Further, our results confirmed the *MYH7* and *MYBPC3* pathogenic variants that have been identified in the original paper, highlighting the variant-calling pipeline and that the results are reliable. Second, the clinical measurement of the studied sample is not fully characterized (such as morphological or magnetic resonance imaging data). This limited our genotype--phenotype correlations, especially for evaluating the clinical outcome differences between the patients carry muti-genic and single gene mutation. Third, the larger sample size would be beneficial for covering broader variants' spectrum and increase the statistical power for differential expression analysis and gene co-expression network construction.

4. Materials and Methods {#sec4-ijms-21-03040}
========================

4.1. RNA-Seq Data {#sec4dot1-ijms-21-03040}
-----------------

The RNA-seq data of SRP186138 \[[@B12-ijms-21-03040]\] were downloaded from the NCBI Sequence Read Archive database (<https://www.ncbi.nlm.nih.gov/sra/SRP186138>). This data set contains 28 myocardial samples from HCM patients and 9 samples from healthy donors. The detailed clinical characteristics of the studied samples are listed in [Table 1](#ijms-21-03040-t001){ref-type="table"}.

4.2. Read Mapping and Variant Calling {#sec4dot2-ijms-21-03040}
-------------------------------------

The raw reads for each sample first underwent adaptor trimming and filtering with the fastp software \[[@B64-ijms-21-03040]\], allowing for reads containing over 80% bases with a quality greater than 20 to be included. Read mapping and variant calling were done according to the Broad Institute's GATK \[[@B65-ijms-21-03040]\] best practices workflow for SNP and Indel calling on RNAseq data (<https://software.broadinstitute.org/gatk/documentation/article.php?id=3891>). Briefly, paired-end reads (PE300) were mapped onto the human reference genome (GRCh38) using the STAR 2-pass alignment method \[[@B66-ijms-21-03040]\]. The first-pass alignment was used to generate the junction file. Then, the second-pass alignment was conducted with the junctions found in the first-pass mapping to produce the final alignments. After that, Picardtools (<http://broadinstitute.github.io/picard/>) was used to add read groups, sort, mark duplicates, and create index. Then, the SplitNCigarReads function, implemented in GATK, was used to split reads into exon segments. Finally, variant calling and filtering were done with HaplotypeCaller and VariantFiltration, respectively.

4.3. Functional Variants and Gene Prioritization {#sec4dot3-ijms-21-03040}
------------------------------------------------

The variant call was first annotated with wANNOWAR \[[@B67-ijms-21-03040]\]. Then, the following strategies were applied to identify potential functional variants and genes: 1) variants only present in the 28 HCM patients, but not in the 9 controls; 2) variants classified as nonsynonymous, stop-gain, stop-loss, frameshift, or splice altering; 3) variants with a minor allele frequency less than 0.01 in 1000G, ExAC, ESP6500, or gnomeAD data sets; 4) variants predicted to be deleterious by no less than five of the following algorithms---SIFT, Polyphen2, LRT, MutationTaster, FATHMM, PROVEAN, MetaSVM, and CADD, and 5) variants only in the 73-gene HCM panel listed in Supplementary Data 1.

4.4. Differential Expression Analysis {#sec4dot4-ijms-21-03040}
-------------------------------------

A comparison of HCM patients with normal controls was used to identify differentially expressed genes (DEGs). Gene-level read counts were obtained using featureCount version 0.6.1 with Ensembl annotation of the GRCh38 reference genome, which includes both coding and non-coding genes. Raw counts were analyzed with DESeq2 version 1.10.1 \[[@B68-ijms-21-03040]\] to identify DEGs. *p*-values were adjusted with the false discovery rate (FDR) based on Benjamini and Hochberg's method \[[@B69-ijms-21-03040]\], and DEGs were defined as FDR \< 0.05 and fold change \> 1.5.

4.5. MiRNA Target Prediction {#sec4dot5-ijms-21-03040}
----------------------------

MiRNAs are a class of non-coding small RNAs (\~22 nucleotides), which are widely found in plant and animal cells. Cleavage of mRNA transcripts or the inhibition of translation initiation is achieved by inaccurate complementary base pairing with the target gene \[[@B70-ijms-21-03040]\]. To date, several algorithms have been proposed and applied to predict miRNAs targets \[[@B71-ijms-21-03040]\]. In this study, we used miRWalk 2 \[[@B72-ijms-21-03040]\], which implements the four miRNA-gene prediction programs "miRWalk," "miRanda", "RNA22", and "Targetscan" to predict miRNA gene targets. We considered the positive target pairs for which more than two algorithms had signals.

4.6. LncRNA Annotation {#sec4dot6-ijms-21-03040}
----------------------

LncRNAs are a class of non-coding RNAs that are greater than 200 nucleotides in length \[[@B73-ijms-21-03040]\]. Although most of them have not been functionally characterized, studies have shown that they play significant roles in gene expression regulation, especially for neighboring genes, at various levels, such as transcriptional and post-transcriptional regulation \[[@B73-ijms-21-03040],[@B74-ijms-21-03040]\]. In order to interpret the potential functional roles of the differentially expressed lncRNAs, their neighbor genes (\< 0.5 Mb) were extracted using bedtools \[[@B75-ijms-21-03040]\] and further explored by performing gene set enrichment analysis.

4.7. Co-Expression Network Analysis {#sec4dot7-ijms-21-03040}
-----------------------------------

Gene co-expression networks was constructed using the WGCNA package in R \[[@B76-ijms-21-03040]\], according to the tutorials written by Peter Langfelder and Steve Horvath (<https://horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/Tutorials/>). We first normalized the raw read count with the Transcripts Per Million (TPM) method and then removed genes whose expression was consistently low (TPM \< 10 in more than 90% of the samples). The filtered data was log-transformed with log2(x+1), which was used as input for WGCNA analysis. Based on the scale-free topology, threshold power β = 5 was used for constructing the adjacency matrix and the Topological Overlap Matrix. Then, genes were aggregated into modules with hierarchical clustering and further refined using the dynamic tree cut algorithm. In order to identify the clinical-trait-associated modules, we performed Pearson's correlation coefficient analysis between the traits and MEs, which are defined as the first principal component of a given module.

4.8. PPI Network Analysis {#sec4dot8-ijms-21-03040}
-------------------------

The PPI network analysis of module genes was based on the protein interaction information retrieved from the online database STRING (<https://string-db.org/>) \[[@B77-ijms-21-03040]\]. To define subnetworks, we first only selected genes with a high confidence interaction score (\> 0.7). Those highly confident interactions were further clustered into subnetworks with the MCL clustering method, for which the inflation parameter was set to 3.

4.9. Gene Over-Representation Analysis {#sec4dot9-ijms-21-03040}
--------------------------------------

Gene overrepresentation analysis for GO (biological process) and KEGG pathway was analyzed with WebGestalt (<http://www.webgestalt.org/>) with default parameters \[[@B78-ijms-21-03040]\]. The human genome was used as a reference gene set, and the minimum number of genes for a category was set to 5 for both analyses. The Benjamini and Hochberg correction \[[@B69-ijms-21-03040]\] was used for multiple test correcting. A threshold of FDR \< 0.05 was used to determine the significantly enriched terms.

4.10. Data Statement {#sec4dot10-ijms-21-03040}
--------------------

Raw RNA-seq data had been deposited in the NCBI Sequence Read Archive database (SRA; <https://www.ncbi.nlm.nih.gov/sra/>) under the accession number SRP186138 \[[@B12-ijms-21-03040]\].

5. Conclusions {#sec5-ijms-21-03040}
==============

In summary, by analyzing myocardial RNA-seq data from HCM and control patients, we provide evidence that HCM is a complex genetic disorder, with pathogenic and modifier protein-coding mutations, differential gene expression, and non-coding RNA modulation contributing to extensive phenotypic variability. In addition, this work highlights the importance of integrative analysis with gene co-expression and protein--protein interaction networks for the further identification of functional HCM genes within gene subnetworks. Further elucidation of HCM genes, whether at the level of the single protein-coding gene or the gene network, will lead to improvements in genetic screening for HCM patients without an identified genetic cause and to the development of new, personalized therapeutics.

Supplementary Materials can be found at <https://www.mdpi.com/1422-0067/21/9/3040/s1>.
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![Workflow for functional variants and gene prioritization.](ijms-21-03040-g001){#ijms-21-03040-f001}

![Heatmap of the pathogenic genes across hypertrophic cardiomyopathy (HCM) patients. Red rectangles represent HCM patients (rows) who carry pathogenic variant(s) in the corresponding gene(s) (columns).](ijms-21-03040-g002){#ijms-21-03040-f002}

![Differentially expressed protein-coding genes between HCM patients and normal controls. (**A**) Volcano plot of the differentially expressed genes (DEGs). The *x*-axes show the log2 transformed fold change, and the *y*-axes show the log10 transformed false discovery rate (FDR). Red dots are DEGs with an FDR \< 0.05 and fold change \> 1.5. (**B--D**) Dot plots of the expression levels of *ANKRD1*, *TGFB3*, and *FHL2* in normal controls (NC) and HCM patients, \*\*\*FDR \< 0.001. (**E**) Bar plots of the significantly enriched cardiovascular-related Gene Ontology (GO) terms for the differentially expressed protein-coding genes.](ijms-21-03040-g003){#ijms-21-03040-f003}

![Correlation networks for the cardiovascular-related differentially expressed protein-coding genes. The Pearson correlation coefficient analysis was calculated across the 192 cardiovascular-related genes. Nodes represent genes, and edges represent correlations between two genes (FDR \< 0.01).](ijms-21-03040-g004){#ijms-21-03040-f004}

![Differentially expressed microRNAs (miRNAs) between HCM patients and normal controls. (**A**--**F**) Dot plots of *miR-487a*, *miR-654*, *miR-30d*, *miR-154*, *miR-3193*, and *miR-3671* expression levels in NC and HCM patients, \*FDR \< 0.05, \*\*FDR \< 0.01, \*\*\*FDR \< 0.001. (**G**) Predicted miRNA-gene pairs with miRWalk2, which implements four miRNA-gene prediction algorithms. Target pairs for which more than two algorithms had signals are included. Seventy-five cardiovascular-related DEGs were targeted by the above miRNAs, with these genes demonstrating inverse expression patterns compared to their corresponding miRNAs.](ijms-21-03040-g005){#ijms-21-03040-f005}

![Co-expression network analysis. (**A**) The soft thresholding index R^2^ (*y*-axis) as a function of the different thresholding power β (*x*-axis). (**B**) Mean connectivity (*y*-axis) as a function of the power β (*x*-axis). (**C**) Sixteen co-expression modules identified from the myocardial RNA-seq dataset. Each cell represents the correlation coefficient *p*-value computed from correlating the module eigengenes to the clinical traits (columns). Cells filled with red represent significant associations between modules and traits (*p* \< 0.05).](ijms-21-03040-g006){#ijms-21-03040-f006}

![MtDNA-, DSP-, MYH7-, and MYBPC3-subnetworks constructed by integrating co-expression and protein--protein interaction (PPI) network analyses. MHY7- and MYBPC3-involved co-expression modules (M14 and M16) identified by co-expression analysis were used to construct PPI-subnetworks from the STRING database (<https://string-db.org/>) with the Markov Cluster (MCL) clustering method, for which the inflation parameter was set to 3.](ijms-21-03040-g007){#ijms-21-03040-f007}

ijms-21-03040-t001_Table 1

###### 

Clinical characteristics of the studied samples \[[@B12-ijms-21-03040]\].

  Sample ID   Group^\#^   Sex      Age   Smoking   LAD (mm)^a^   LVST (mm)^b^   LVEDD (mm)^c^   LVEF (%)^d^   Maxi LVWT (mm)^e^   Maxi LVOTG (mmHg)^f^
  ----------- ----------- -------- ----- --------- ------------- -------------- --------------- ------------- ------------------- ----------------------
  HCM420      GENETUN     male     32    NA        41            14             44              76            18                  55
  HCM405      GENETUN     female   31    NO        42            14             47              78            16                  126
  HCM541      GENETUN     male     38    NA        47            22             46              71            25                  96
  HCM493      GENETUN     male     40    NA        40            15             45              75            17                  95
  HCM273      GENETUN     male     30    NO        38            15             33              50            21                  30
  HCM269      GENETUN     male     25    NO        53            29             51              63            38                  56
  HCM395      GENETUN     male     20    NO        49            19             43              60            22                  78
  HCM282      GENETUN     male     48    YES       49            21             49              65.3          23                  75
  HCM591      GENETUN     male     42    NA        39            21             45              70            32                  53
  HCM552      GENETUN     male     32    NA        NA            NA             NA              75            21                  100
  HCM515      *MYBPC3*    male     21    YES       39            18             50              75            25                  84
  HCM504      *MYBPC3*    male     25    YES       39            25             39              75            28                  66
  HCM498      *MYBPC3*    male     39    YES       38            20             42              72            21                  55
  HCM486      *MYBPC3*    female   36    NA        45            16             35              75            20                  100
  HCM460      *MYBPC3*    male     43    YES       45            16             45              65            19                  61
  HCM439      *MYBPC3*    female   47    NA        36            15             38              80            18                  103
  HCM437      *MYBPC3*    male     30    YES       54            19             47              78            26                  54
  HCM429      *MYBPC3*    female   36    NA        48            17             42              78            18                  70
  HCM533      *MYBPC3*    male     47    YES       62            24             50              75            29                  118
  HCM518      *MYBPC3*    female   31    NA        37            22             38              68            26                  105
  HCM506      *MYH7*      male     19    YES       48            20             43              75            21                  59
  HCM562      *MYH7*      female   36    YES       36            0              36              66            21                  70
  HCM490      *MYH7*      female   41    NA        44            15             39              58            21                  63
  HCM491      *MYH7*      female   30    NA        44            23             32              75            28                  64
  HCM456      *MYH7*      male     28    NA        51            15             45              69            20                  90
  HCM483      *MYH7*      male     37    YES       57            23             40              72            26                  70
  HCM431      *MYH7*      male     24    NA        57            18             49              80            21                  80
  HCM443      *MYH7*      female   28    NA        46            17             44              69            18                  68
  sc5-LV      NORMAL      female   NA    NA        NA            NA             NA              NA            NA                  NA
  sc2-LV      NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  sc6-LV      NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  N105-LV     NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  N104-LV     NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  ND2         NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  ND1-LV      NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  N102-LV     NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA
  N103-LV     NORMAL      male     NA    NA        NA            NA             NA              NA            NA                  NA

^\#^: GENETUN, genetically undiagnosed HCM patient; *MYBPC3*, HCM patient with mutation in *MYBPC3*; *MYH7*, HCM patient with mutation in *MYH7*; NORMAL, normal heart; ^a^: left atrial diameter; ^b^: left ventricular septal thickness; ^c^: left ventricular end-diastolic; ^d^: left ventricular ejection fraction; ^e^: maximum left ventricular wall thickness; ^f^: maximum left ventricular outflow track gradient at rest or after exercise; NA: not available.

ijms-21-03040-t002_Table 2

###### 

Summary statistics of RNA-seq data.

  Sample ID   Raw Reads     HQ Reads      HQ Reads (%)   Mapping Rate (%) ^\#^   Total Variant   Exonic Variant
  ----------- ------------- ------------- -------------- ----------------------- --------------- ----------------
  HCM420      117,254,002   110,409,284   94.16          96.87                   742,007         34,208
  HCM405      96,660,588    90,958,152    94.10          96.72                   697,916         32,501
  HCM541      118,364,902   112,199,122   94.79          96.56                   748,918         34,438
  HCM493      135,595,138   127,235,398   93.83          96.67                   802,057         35,285
  HCM273      100,383,614   94,562,944    94.20          96.10                   674,997         32,320
  HCM269      104,573,612   98,483,828    94.18          96.69                   657,403         30,937
  HCM395      101,463,898   94,778,784    93.41          96.50                   718,773         32,792
  HCM282      135,385,378   128,496,976   94.91          96.41                   835,560         36,065
  HCM591      117,087,250   110,633,048   94.49          96.33                   742,357         33,694
  HCM552      110,633,048   97,644,508    88.26          96.57                   714,914         32,157
  HCM515      126,385,206   120,132,036   95.05          96.53                   797,070         35,707
  HCM504      126,614,812   120,041,188   94.81          96.46                   747,293         34,481
  HCM498      118,114,640   110,661,262   93.69          96.18                   745,414         33,633
  HCM486      102,005,260   95,821,344    93.94          96.76                   688,159         32,517
  HCM460      83,321,826    78,346,916    94.03          97.01                   641,381         30,658
  HCM439      115,966,430   108,531,416   93.59          96.48                   777,052         34,950
  HCM437      114,409,150   107,630,394   94.07          96.59                   718,353         33,216
  HCM429      107,327,856   100,460,638   93.60          96.51                   781,013         34,514
  HCM533      113,801,296   107,068,190   94.08          96.47                   765,001         34,584
  HCM518      123,140,430   116,174,372   94.34          96.54                   821,103         36,229
  HCM506      104,464,396   98,442,104    94.24          96.88                   721,500         33,453
  HCM562      119,176,332   113,518,840   95.25          96.63                   782,848         34,382
  HCM490      109,178,274   102,325,212   93.72          96.79                   728,218         33,873
  HCM491      123,213,328   115,698,990   93.90          95.97                   756,623         34,040
  HCM456      124,188,740   116,826,920   94.07          96.65                   793,088         35,368
  HCM483      132,375,212   125,845,538   95.07          96.52                   838,862         35,806
  HCM431      95,467,544    91,611,504    95.96          96.60                   701,266         33,263
  HCM443      103,385,170   96,969,874    93.79          96.18                   707,524         33,016
  sc5-LV      115,206,460   109,427,776   94.98          94.80                   731,586         35,144
  sc2-LV      119,628,518   113,668,538   95.02          96.52                   747,079         34,629
  sc6-LV      133,156,688   126,807,678   95.23          95.59                   789,274         37,289
  N105-LV     125,064,692   118,533,240   94.78          96.39                   830,057         35,975
  N104-LV     151,765,118   143,413,882   94.50          96.50                   930,969         37,875
  ND2         115,981,584   110,192,388   95.01          94.90                   649,196         33,173
  ND1-LV      111,029,746   105,848,092   95.33          95.66                   715,284         33,920
  N102-LV     111,141,904   102,446,288   92.18          96.59                   754,272         33,343
  N103-LV     146,673,012   138,682,818   94.55          96.50                   864,176         35,856

**^\#^**: the percentage of uniquely mapped reads to the total high-quality (HQ) reads.
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###### 

Lists of candidate variants prioritized from HCM patients.

  Group     Sample ID     Gene            dbSNP                                   Variant Type                                 AAChange^\#^
  --------- ------------- --------------- --------------------------------------- -------------------------------------------- -----------------------------------------------
  GENETUN   HCM541        *ABCC9*         rs763968252                             nonsynonymous                                NM_005691:exon24:c.T2935C:p.W979R
  HCM493    *SGCD*        rs397516338     nonsynonymous                           NM_001128209:exon8:c.A845G:p.Q282R           
  *TTN*     rs146400809   nonsynonymous   NM_133378:exon126:c.C28730T:p.P9577L                                                 
  HCM395    *CSRP3*       NA              stop loss                               NM_003476:exon7:c.A585C:p.X195C              
  HCM282    *NEXN*        rs146245480     nonsynonymous                           NM_001172309:exon7:c.C643T:p.R215C           
  HCM591    *DSP*         rs116888866     nonsynonymous                           NM_001008844:exon24:c.G6119A:p.R2040Q        
  *PSEN2*   rs574125890   nonsynonymous   NM_000447:exon8:c.G640T:p.V214L                                                      
  HCM552    *NEBL*        rs75301590      nonsynonymous                           NM_006393:exon6:c.G561C:p.Q187H              
  MYBPC3    HCM515        *MYBPC3*        rs869025465                             frameshift deletion                          NM_000256:exon13:c.1153_1168del:p.V385Mfs\*15
  *NEXN*    rs146245480   nonsynonymous   NM_001172309:exon7:c.C643T:p.R215C                                                   
  *LDB3*    rs566463138   nonsynonymous   NM_001080114:exon10:c.T1367G:p.M456R                                                 
  *TNNT2*   rs141121678   nonsynonymous   NM_001001432:exon14:c.G839A:p.R280H                                                  
  HCM504    *MYBPC3*      NA              frameshift deletion                     NM_000256:exon28:c.3018delC:p.W1007Gfs\*12   
  *TTN*     rs118161093   nonsynonymous   NM_003319:exon27:c.G5602A:p.A1868T                                                   
  *TTN*     rs139517732   nonsynonymous   NM_001256850:exon3:c.G160A:p.V54M                                                    
  HCM498    *MYBPC3*      NA              stop gain                               NM_000256:exon5:c.G587A:p.W196X              
  *ACTN2*   rs376144003   nonsynonymous   NM_001103:exon11:c.T1162A:p.W388R                                                    
  *PSEN2*   NA            nonsynonymous   NM_000447:exon10:c.C902A:p.T301K                                                     
  HCM486    *PLN*         NA              nonsynonymous                           NM_002667:exon2:c.T106C:p.C36R               
  HCM460    *MYBPC3*      rs730880576     stop gain                               NM_000256:exon26:c.G2748A:p.W916X            
  *LDB3*    rs397517221   nonsynonymous   NM_001080114:exon2:c.C236T:p.T79I                                                    
  *TTN*     rs199932621   nonsynonymous   NM_003319:exon186:c.G75632A:p.R25211Q                                                
  HCM439    *MYBPC3*      rs397516073     splicing                                NA                                           
  *LAMA4*   rs3752579     nonsynonymous   NM_001105206:exon12:c.T1475A:p.L492H                                                 
  *PSEN2*   NA            nonsynonymous   NM_000447:exon13:c.G1234A:p.A412T                                                    
  HCM437    *MYBPC3*      NA              frameshift insertion                    NM_000256:exon13:c.1201dupC:p.Q401Pfs\*12    
  *MYH7*    rs727503278   nonsynonymous   NM_000257:exon5:c.C427T:p.R143W                                                      
  *COX15*   rs769275933   nonsynonymous   NM_001320976:exon9:c.C584T:p.T195M                                                   
  HCM429    *MYBPC3*      NA              frameshift deletion                     NM_000256:exon22:c.2237delA:p.E746Gfs\*6     
  *NEXN*    rs146245480   nonsynonymous   NM_001172309:exon7:c.C643T:p.R215C                                                   
  HCM533    *MYBPC3*      NA              stop gain                               NM_000256:exon24:c.C2526G:p.Y842X            
  *TTN*     rs549841864   nonsynonymous   NM_003319:exon167:c.C66059T:p.P22020L                                                
  HCM518    *MYBPC3*      NA              frameshift deletion                     NM_000256:exon4:c.480delG:p.P161Hfs\*5       
  MYH7      HCM506        *MYH7*          rs121913627                             nonsynonymous                                NM_000257:exon16:c.G1816A:p.V606M
  *RBM20*   rs372923744   nonsynonymous   NM_001134363:exon9:c.G2201A:p.R734Q                                                  
  HCM562    *MYH7*        rs727503278     nonsynonymous                           NM_000257:exon5:c.C427T:p.R143W              
  *DSP*     rs116888866   nonsynonymous   NM_001008844:exon24:c.G6119A:p.R2040Q                                                
  HCM490    *MYH7*        rs397516201     nonsynonymous                           NM_000257:exon30:c.C4130T:p.T1377M           
  *TTN*     rs368057764   nonsynonymous   NM_003319:exon79:c.C19652T:p.T6551M                                                  
  *TTN*     *NA*          nonsynonymous   NM_003319:exon154:c.G56641A:p.D18881N                                                
  *TTN*     rs567446185   nonsynonymous   NM_003319:exon154:c.G46322A:p.G15441D                                                
  HCM491    *MYH7*        rs397516127     nonsynonymous                           NM_000257:exon18:c.C1987T:p.R663C            
  *MYH6*    NA            splicing        NA                                                                                   
  HCM456    *MYH7*        rs3218714       nonsynonymous                           NM_000257:exon13:c.C1207T:p.R403W            
  HCM483    *MYH7*        rs121913627     nonsynonymous                           NM_000257:exon16:c.G1816A:p.V606M            
  HCM431    *MYH7*        rs727503246     nonsynonymous                           NM_000257:exon30:c.G4066A:p.E1356K           
  *PSEN1*   NA            splicing        NA                                                                                   
  HCM443    *MYH7*        rs121913632     nonsynonymous                           NM_000257:exon20:c.G2221T:p.G741W            
  *NEBL*    rs75301590    nonsynonymous   NM_006393:exon6:c.G561C:p.Q187H                                                      

\#: Gene may have multiple transcript annotations, but only the first is shown here; the full list of annotations can be found in [Supplementary Data 2](#app1-ijms-21-03040){ref-type="app"}; NA: not available.
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###### 

GO enrichment of long noncoding RNA (lncRNA)-annotated protein-coding genes.

  GO Term      Description                                          Gene Count   *p*-value        FDR
  ------------ ---------------------------------------------------- ------------ ---------------- ----------------
  GO:0072358   cardiovascular system development                    95           6.21 × 10^−14^   8.38 × 10^−11^
  GO:0007507   heart development                                    75           2.71 × 10^−10^   1.10 × 10^−7^
  GO:0003007   heart morphogenesis                                  42           7.29 × 10^−9^    1.89 × 10^−6^
  GO:0003231   cardiac ventricle development                        26           1.18 × 10^−7^    1.61 × 10^−5^
  GO:0003206   cardiac chamber morphogenesis                        25           6.39 × 10^−7^    6.43 × 10^−5^
  GO:0003205   cardiac chamber development                          29           1.09 × 10^−6^    9.88 × 10^−5^
  GO:0048738   cardiac muscle tissue development                    31           4.73 × 10^−6^    3.00 × 10^−4^
  GO:0060411   cardiac septum morphogenesis                         16           5.09 × 10^−6^    3.11 × 10^−4^
  GO:0003208   cardiac ventricle morphogenesis                      17           7.56 × 10^−6^    4.43 × 10^−4^
  GO:0035051   cardiocyte differentiation                           22           2.22 × 10^−5^    1.12 × 10^−3^
  GO:0003279   cardiac septum development                           19           3.35 × 10^−5^    1.59 × 10^−3^
  GO:0003215   cardiac right ventricle morphogenesis                8            3.44 × 10^−5^    1.62 × 10^−3^
  GO:0003197   endocardial cushion development                      11           8.84 × 10^−5^    3.62 × 10^−3^
  GO:1905207   regulation of cardiocyte differentiation             10           2.19 × 10^−4^    7.33 × 10^−3^
  GO:0003203   endocardial cushion morphogenesis                    9            2.62 × 10^−4^    8.54 × 10^−3^
  GO:0055007   cardiac muscle cell differentiation                  17           3.08 × 10^−4^    9.57 × 10^−3^
  GO:0055008   cardiac muscle tissue morphogenesis                  13           3.15 × 10^−4^    9.72 × 10^−3^
  GO:0060047   heart contraction                                    33           5.04 × 10^−4^    1.46 × 10^−2^
  GO:0003015   heart process                                        33           6.21 × 10^−4^    1.72 × 10^−2^
  GO:0035050   embryonic heart tube development                     14           6.58 × 10 ^−4^   1.80 × 10^−2^
  GO:0055017   cardiac muscle tissue growth                         13           6.92 × 10^−4^    1.88 × 10^−2^
  GO:0061323   cell proliferation involved in heart morphogenesis   6            7.55 × 10^−4^    1.98 × 10^−2^
  GO:0055012   ventricular cardiac muscle cell differentiation      6            7.55 × 10^−4^    1.98 × 10^−2^
  GO:1905209   positive regulation of cardiocyte differentiation    7            1.00 × 10^−3^    2.44 × 10^−2^
  GO:0003170   heart valve development                              9            1.27 × 10^−3^    2.97 × 10^−2^
  GO:0003272   endocardial cushion formation                        7            1.31 × 10^−3^    3.02 × 10^−2^
  GO:0010002   cardioblast differentiation                          6            1.46 × 10^−3^    3.32 × 10^−2^
  GO:0060419   heart growth                                         13           1.59 × 10^−3^    3.52 × 10^−2^
  GO:0003143   embryonic heart tube morphogenesis                   12           1.73 × 10^−3^    3.78 × 10^−2^
  GO:2000725   regulation of cardiac muscle cell differentiation    7            2.14 × 10^−3^    4.40 × 10^−2^
  GO:0001947   heart looping                                        11           2.44 × 10^−3^    4.85 × 10^−2^

[^1]: These authors contributed equally.
